Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01603069 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

A Phase 2 study of Parkinson's Disease, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
51
Enrollment target
13
Study locations

NCT01603069 is a Phase 2 study of Parkinson's Disease that has completed, run by AstraZeneca. The registered enrollment target is 51 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (92% lower). The trial reports 13 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01603069, a Phase 2 study of Parkinson's Disease, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
51 participants
Enrollment target
13
Study locations

Study Summary

This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.

Conditions Studied

Parkinson's Disease

Interventions

  • DRUG Placebo
  • DRUG AZD3241 300 mg BID
  • DRUG AZD3241 600 mg BID

Study Locations (13)

Florida

  • Research Site - Atlantis
  • Research Site - Boca Raton
  • Research Site - Orlando
  • Research Site - Sunrise
  • Research Site - Tampa

New Jersey

  • Research Site - Lawrenceville
  • Research Site - Marlton

Alabama

  • Research Site - Birmingham

California

  • Research Site - Long Beach

Connecticut

  • Research Site - New Haven

Kansas

  • Research Site - Kansas City

Michigan

  • Research Site - Bingham Farms

Nebraska

  • Research Site - Omaha

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2012-10
Est. Completion 2013-06
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01603069

The ClinicalTrials.gov registry entry for NCT01603069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (92% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01603069 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Florida, New Jersey, Alabama.

Frequently Asked Questions

What is clinical trial NCT01603069 about?

NCT01603069 is a clinical study titled "A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease". This is a study where AZD3241 or placebo is given to patients with Parkinson's disease in a blinded and randomized assignment. The main objective is to see if safety and tolerability of the drug is acceptable.

What is the current status of trial NCT01603069?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2012-10. Estimated completion is 2013-06.

What conditions does trial NCT01603069 study?

This clinical trial studies the following conditions: Parkinson's Disease.

What interventions are being tested in trial NCT01603069?

The interventions under investigation include: Placebo (DRUG), AZD3241 300 mg BID (DRUG), AZD3241 600 mg BID (DRUG).

Who is sponsoring clinical trial NCT01603069?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01603069 being conducted?

This trial has 13 study locations across Alabama, California, Connecticut, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.